$9.01
1.21% yesterday
Nasdaq, Jun 27, 10:13 pm CET
ISIN
US92556V1061
Symbol
VTRS

Viatris Stock News

Neutral
PRNewsWire
2 days ago
MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Compromising Distance Vision Safety Profile Consistent With Previous Clinical Trials And No Treatment-Related Serious Adverse Events Reported In This Study Targeting Application To U.S. FDA In Second Half of 2025 PITTSBURGH , June 26, 2025 /PRNewswire/ -- Viatris Inc. (Nas...
Neutral
PRNewsWire
15 days ago
PITTSBURGH , June 12, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 a.m.
Neutral
GlobeNewsWire
18 days ago
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viatris Inc. (NASDAQ: VTRS) breached their fiduciary duties to shareholders.
Neutral
Seeking Alpha
19 days ago
Viatris Inc. (NASDAQ:VTRS ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 10:40 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Scott Andrew Smith - CEO & Director Conference Call Participants Unidentified Analyst Great.
Neutral
Seeking Alpha
23 days ago
Viatris Inc. (NASDAQ:VTRS ) Jefferies Global Healthcare Conference June 5, 2025 8:10 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Theodora Mistras - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Yuchen Ding Good morning, and welcome to the day 2 of the Jefferies Healthcare Conference.
Neutral
Business Wire
25 days ago
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025, both dates inclusive (the “Class Period”). Viatris describes itself as a “global healthcare company, which engages in the provision of healthcare and pharmac...
Neutral
GlobeNewsWire
26 days ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Viatris To Contact Him Directly To Discuss Their Options
Neutral
PRNewsWire
26 days ago
LOS ANGELES , June 2, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS). IF YOU SUFFERED A LOSS ON YOUR VIATRIS INVESTMENTS, CLICK HERE BEFORE JUNE 3, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT ...
Show more news

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today